C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Presenter disclosure information name: Frank Uhlemann In the last 12 month.

Slides:



Advertisements
Similar presentations
Dr.Bandar Al Hubaishy Urology Department KAUH
Advertisements

“PFO Closure: anatomical variants and implications for choice of procedure, success rates and complications” LM Shapiro. Papworth Hospital, Cambridge.
بسم الله الرحمن الرحيم بسم الله الرحمن الرحيم.
STROKESTROKESTROKESTROKE. Why Change? Improve Mortality Improve Mortality Devastating and Life Altering Devastating and Life Altering Cost expense of.
Disclosure Information Devices for ASD&PFO Closure: Amplatzer Devices As a faculty member for this program, I disclose the following relationships with.
Indications for intervention of ASD and VSD
STROKE Dr Muhammah Ashraf Assistant Professor Medicine
Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.
Stroke Issues & prevention. Agenda  Impact of Stroke –Definitions –Epidemiology –Risk factors  Management of Stroke –Acute management –Primary & Secondary.
Percutaneous Closure of Patent Foramen Ovale Sponsors: Kung Ming Jan, M.D., Ph.D. Judah Weinberger, M.D., Ph.D. Columbia University Medical Center Department.
Copyright © 2005 Pearson Education, Inc., publishing as Benjamin Cummings PowerPoint ® Lecture prepared by Jan Campbell T H E B A S I C S SIXTH EDITION.
By: Mark Torres Anatomy and Physiology II TR 3:15- 6:00.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
DR. HANA OMER CONGENITAL HEART DEFECTS. The major development of the fetal heart occurs between the fourth and seventh weeks of gestation, and most congenital.
Vertebral Artery Stenting VIST meeting 12 th October Dr Andrew Clifton Atkinson Morley Wing St George’s Hospital.
Hemodynamic Monitoring By Nancy Jenkins RN,MSN. What is Hemodynamic Monitoring? It is measuring the pressures in the heart.
Migraine Intervention with STARFlex Technology (MIST) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Andrew.
Atrial Septal Defect Dr. mahsa ghasemi.
Secondary prevention after a TIA or ischemic stroke.
Current Status and Prospect of Interventional Congenital Heart Disease
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
Background In the absence of diffuse atherosclerosis or aneurysms, TAMT are exceedingly rare Cerebral, visceral and peripheral arterial emboli are a common.
PFO Dr Peter Wilmshurst Royal Shrewsbury Hospital Co-workers: Simon Nightingale, Lindsay Morrison, Matthew Pearson, Kevin Walsh, Phil Bryson, John Davis,
Endovascular management of CCSVI: Single Center Experience Hector Ferral, MD, George Behrens, MD, Yanki Tumer, MD, Tameem Souman, MD.
Indication and contra-indications for cardiac catheterization
Mitral Valve Disease Prof JD Marx UFS January 2006.
Angiography and Arteriography SPRING 2009 FINAL
Transhepatic venous cardiac catheterization
The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.
Pediatric Interventions Cardiac Catheterization and Valvuloplasty.
UNEXPECTED CAUSE(S) OF CEREBRAL MICROEMBOLISATION INVESTIGATED BY TRANSCRANIAL DOPPLER DUPLEX COLOUR SONOGRAPHY Muriel SPRYNGER Cardiology-Angiology CHU.
Transcatheter ASD closure, sans X-rays Peter Ewert MD Robert Beekman MD.
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
Fontan Procedure Ken Jusko, DO. Case 39 yo female with h/o tricuspid atresia and A. fib. and prior Fontan. No prior studies available for comparison.
Treatment of Ischaemic Stroke The American Heart Association American Stroke Association Guidelines Stroke. 2007;38:
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Update on TIA Kath Pasco October  Primary prevention has been effective in fall in incidence of first stroke  Major improvements still required.
Secondary Intervention in Unfavorable AAA Neck Anatomy Congress Symposium 2007 John T. Collins, MD Borgess Medical Center Kalamazoo, MI.
How do you manage this patient?. Diagnostic An adequate diagnostic workup: Documents the presence and type of ASD(s) Determines the size (diameter) of.
CONGENITAL HEART DEFECTS DR. HANA OMER. CONGENITAL HEART DEFECTS D. HANA OMER.
Dr. Meg-angela Christi M. Amores
By M.elkhatib.  Equal  R = L  Q refers to flow  Therefore Qp = Qs  Blood flow to both the pulmonary & systemic circulations is balanced.  Homeostasis.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Practice Parameter: Risk of Recurrent Stroke and Secondary Stroke Prevention in Patients With Interatrial Septal Abnormalities (An Evidence-Based Review)
Cardioembolic Stroke: Diagnosis and Management
Ted Feldman MD, FACC, FESC, FSCAI Disclosure Information The following relationships exist: Grant support: Abbott, BSC, Edwards, St Jude, WL Gore Consultant:
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Imaging the Left Atrial Appendage Prior to, During,
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Closure of Atrial Septal Defects With the Amplatzer.
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural.
Causes of Heart Valve Dysfunction Congenital defects (bicuspid aortic valve) Infections (rheumatic fever and bacterial endocarditis Coronary artery disease.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Double lumen remodeling balloon: New technique for treatment of MCA bifurcation aneurysm Kadziolka K, Leautaud A., Estrade L., W. Mustafa, Pierot L. CHU.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.
VSD post TAVR: Mechanisms, Presentation and Management
M-Guard stent in STEMI patients with high thrombus burden lesions Mahmoud Shabestari Baktash Bayani Ali Eshraghi Bahram Shahri Mashhad University.
Disclosure Statement of Financial Interest Saibal Kar, MD, FACC
Prof. Dr. med. H. R. Figulla Director at the University Hospital Jena
Dr. M. A. Sofi MD; FRCP (London); FRCPEdin; FRCSEdin
Challenging Case Presentation For Structural Heart Disease Program
Update on PFO stents Mark Reisman, M.D., F.A.C.C.
Essential Imaging Tools
EVOLUT R, Next Generation, and Future
Successful retrieval of embolized atrial septal defect and patent foramen ovale closure device using novel coronary wire trap (CWT) technique. Alireza.
30-Day Safety and Echocardiographic Outcomes Following Transcatheter Aortic Valve Replacement with the Self-Expanding Repositionable Evolut PRO System.
A Primer of LAA Closure: and Pattern Recognition
2 A Cardiology Department, University of Athens
A Primer of LAA Closure: and Pattern Recognition
Balu Vaidyanathan, Sumantha Sekhar Padhi, Ananthen KS, BRJ Kannan,
Congenital/Mitral Valve Prolapse
Presentation transcript:

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Presenter disclosure information name: Frank Uhlemann In the last 12 month the presenter had contact to the following companies. There is no conflict of interests companycontact AbbottconsultantF.Uhlemann St. Jude medicalconsultantF.Uhlemann

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Interventional PFO-Closure Using The Premere Device A Single-Center Experience F. Uhlemann Center for Congenital Heart Disease Stuttgart Olgahospital Advanced Angioplasty 2007 London 26th January

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Device design Tether Lock Delivery System Release Mechanism Left Atrial Anchor Right Atrial Anchor

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Device - Optimal anatomic adaptation long Track Keypoints: flexible length of connection between both anchors low content of metal slim design especially on left side Separate steerability of left and right atrial anchor Sizes: (15mm), 20mm and 25mm diameter short Track

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T 30 day porcine implant left atrial anchor right atrial anchor Device - rapid and complete endothelialisation

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Procedure - the way we do it in Stuttgart Pre intervention complete neurologic workup workup for coagulation disorders, e.g. thrombophilia TOE with bubble study and Valsalva During intervention sedation on demand full heparinisation (100 IU/kg, single dose) short term antibiotic prophylaxis Post intervention heparinisation for 24 hours Drugs: commencing 12h post implantation aspirin (low dose) and clopidogrel for 3months aspirin (low dose)for next 3 months Follow up examinations (ecg, echo, holter-ecg, clinical): 3-4 weeks (TOE for thrombus formation) 6 months (TOE for complete closure) 1 year

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Procedure - balloonsizing„sense or nonsense“ low pressure balloon, TOE, echo contrast and abdominal pressure pro: to get an idea of the track morphology, diameter, stiffness, length to exclude additional defects con:expensive, need for longer TOE What you can miss without echo guidance: Chiari network large Eustachian valve overriding of SVC partial anomalous pulmonary venous drainage subdivided left atrium We perform balloon sizing in every patient We recommend echo guidance in every patient

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T The way we do it – intervention/balloonsizing long track versus short track waist at different levels same level

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Deployment of device - steps deployment of left atrial anchor „free floating“ in left atrium self orientation towards the septum deployment of right atrial „patched“ anchor individual steerability and option for repositioning

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Deployment of device - steps locking of both parts and opening of snare true image of the final position before final release final release cutting the tether, superior conformability

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Interventional closure of pFO – patients -device selection n = 69 Implantation periods period 1: from 10/2004 to 05/2005 only 20mm Premere device available period 2: from 06/2005 to 08/ mm and 25mm device available device selection according to patients anatomy patients 99 patients with intention for closure - 99 patients successful closure procedure 69 patients suitable for Premere device and enrolled Age (years): mean +/-SD46,10 +/- 11,05 Range(20 – 75) Male sex % (n)49,3 (34) History of cryptogenic ischaemic stroke % (n)41,8 (29) transient ischaemic attack % (n)58,2 (40) Follow up mean follow up11,1 months

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Results - closure rate ? to our understanding at early stage irrelevant

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Results - complications 69 patients with Premere device major complications: device embolisation1** need for surgerynone thrombus formation left sidenone cerebral events1 TIA* * despite successful closure ** without clinical symptoms minor complications: bleeding (need for transfusion)none thrombus formation right sidenone rhytm disturbances permanentnone rhytm disturbances intercurrent1 need for drug1

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Current limitations for 25mm Premere device pFO morphology wide opening of right or left side of the track (entrapment of the anchor) >15mm very large aneurysm left right shunting (debatable) multiperforated pFO

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Summary- interventional closure of pFO Premere device (St. Jude Medical) good closure rate suitable for about 70% of our unselected patient group easy implantation procedure excellent adaptation to individual anatomy rapid endothelialisation low complication rate

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Thank you

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Possible indications for interventional closure of pFO Neurologic indication (prevention of paradoxical embolism) patients with stroke, PRIND, TIA or other embolic history assumed to be paradoxic patients with severe migraine special patient groups: professional scuba divers (prevention of decompression disease) jet pilots women with evidence of hypercoagulation and wish for pregnancy Hemodynamic indication (prevention of right-left-shunting) RV-failure due to RV-infarction cyanotic patients with COLD

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T interventional closure of pFO follow up, detection of residual shunts TOE sometimes low intensity of valsalva noninvasive- accuracy depends on site of intravenous injection ICE invasive, expensive TCD sometimes low intensity of valsalva noninvasive accuracy depends on site of intravenous injection

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T interventional closure of pFO

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T interventional closure of pFO

C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T interventional closure of pFO